SCHEMBL297907

SCHEMBL297907

CC(C)(C)c1ccc(S(=O)(=O)NNC(=O)C2=CCCN(CC(=O)c3cccs3)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.45
GAA P10253 3/20 0.45
LMNA P02545 3/20 0.40
KDM4E B2RXH2 1/20 0.40
CASP1 P29466 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
HTT P42858 2/20 0.38
MAPT P10636 2/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
HPGD P15428 1/20 0.37
ATM Q13315 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPK1 P28482 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KAT6A Q92794 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL287300 0.89 ALDH1A1 (0.48) ALDH1A1GAALMNAKDM4ECASP1
SCHEMBL287270 0.84 ALDH1A1 (0.47) ALDH1A1GAALMNAKDM4ECASP1
SCHEMBL286776 0.80 ALDH1A1 (0.44) ALDH1A1GAALMNASMN1; SMN2HTT
SCHEMBL661997 0.77 ALDH1A1 (0.49) ALDH1A1GAAKDM4EHTTMEN1
SCHEMBL297771 0.71 GAA (0.46) ALDH1A1GAALMNASMN1; SMN2HTT
SCHEMBL298004 0.71 GFER (0.52) ALDH1A1GAALMNAKDM4ESMN1; SMN2
SCHEMBL298699 0.70 LMNA (0.47) ALDH1A1GAALMNAKDM4ECASP1
SCHEMBL297715 0.70 ALDH1A1 (0.41) ALDH1A1GAAKDM4ECASP1SMN1; SMN2
SCHEMBL297716 0.70 ALDH1A1 (0.41) ALDH1A1GAAKDM4ECASP1SMN1; SMN2
SCHEMBL297717 0.70 ALDH1A1 (0.41) ALDH1A1GAAKDM4ECASP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO claimed
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT ALDH1A1 676/4885GAA 194/4885LMNA 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.